Oxeia Biopharmaceuticals
Oxeia Biopharmaceuticals develops novel therapeutics for patients with concussions, aiming to provide effective treatment options beyond rest. The company is conducting Phase 2 human clinical studies for its therapeutic drug, OXE-103, to treat concussions, and is dedicated to advancing brain injury research and treatment. Additionally, Oxeia is actively involved in research related to traumatic brain injuries (TBI), including those caused by military service, sports, falls, and other accidents. The company emphasizes the importance of treatment development for mTBI, which is recognized as an epidemic with significant long-term health and societal impacts.
Industries
Nr. of Employees
small (1-50)
Oxeia Biopharmaceuticals
San Diego, California, United States, North America
Products
Blood–brain barrier–penetrant synthetic ghrelin therapeutic candidate (lead program)
A synthetic ghrelin-based peptide candidate designed to cross the blood–brain barrier, target hippocampal regions, and address neuro‑metabolic dysfunction and axonal injury following concussion; advanced into Phase II clinical studies with reported symptomatic and quality-of-life outcomes in pilot data.
Blood–brain barrier–penetrant synthetic ghrelin therapeutic candidate (lead program)
A synthetic ghrelin-based peptide candidate designed to cross the blood–brain barrier, target hippocampal regions, and address neuro‑metabolic dysfunction and axonal injury following concussion; advanced into Phase II clinical studies with reported symptomatic and quality-of-life outcomes in pilot data.
Services
Sponsor-led Phase II clinical trials for mTBI therapeutics
Design and conduct of multi-site Phase II clinical studies evaluating BBB-penetrant neuroprotective peptide/hormone therapeutics for mild traumatic brain injury, including symptomatic and emergency-room patient cohorts.
Sponsor-led Phase II clinical trials for mTBI therapeutics
Design and conduct of multi-site Phase II clinical studies evaluating BBB-penetrant neuroprotective peptide/hormone therapeutics for mild traumatic brain injury, including symptomatic and emergency-room patient cohorts.
Expertise Areas
- Clinical trial management
- Translational neuroscience
- Neurotrauma therapeutics development
- Regulatory strategy for early-stage investigational drugs
Key Technologies
- Synthetic peptide/hormone therapeutic design
- Blood–brain barrier permeable delivery approaches
- Hippocampus-targeted neuroprotective strategies
- Translational biomarker assessment for neuro‑metabolic dysfunction